ArticlePediatric blood & cancer2025
Pediatric and Young Adult Cancer Incidence in the United States During the COVID-19 Pandemic.
Article in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pandemic-era increases in late-stage pediatric cancer diagnoses, 2020-2022.JNCI cancer spectrum · 2026Article
- Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study.PLoS medicine · 2026Article
- Article
- Improved survival, disparate outcomes contemporaneously define the modern worldwide burden of childhood cancers.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCancer incidence decreased during the COVID-19 pandemic; this study describes cancer incidence changes for children, adolescents, and young adults during this period. We used US Cancer Statistics (USCS) to describe potential impacts of the pandemic on cancer incidence for persons 0-39 years.
methodsWe used data from USCS, covering 98% of the US population, to evaluate cancer case counts, incidence rates, and monthly counts; incidence rate ratios were calculated comparing year 2019 (baseline) to 2020 and 2021. We calculated trends using joinpoint regression for the period 2003-2021.
resultsComparing 2019 with 2020, cancer incidence decreased 5% (95% confidence interval [CI], 3%-7%) for ages 0-19 years and 7% (95% CI, 6%-8%) for ages 20-39. For ages 0-19, decreases were seen for thyroid cancer, melanoma, and nonmalignant central nervous system (CNS) neoplasms. For ages 20-39, decreases were seen for leukemias, lymphomas, CNS neoplasms, sarcomas, melanoma, and some carcinoma types. Decreases in 2020 were least pronounced for the distant stage at diagnosis. For ages 0-39, new diagnoses were lowest during March or April 2020 but returned to prepandemic levels during the second half of 2020. Decreases in 2021 were consistent with previously decreasing trends for many cancer types.
conclusionsCancer rate decreases were largest for young adults (vs. children) and were significant for some cancer types. These findings might help assess the impacts of the COVID-19 pandemic, inform investigations into potential causes of these decreases, and guide responses to future public health crises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.